The Pharmaceutical Sciences and Pharmacogenomics (PSPG) Graduate Program is a cross-disciplinary program that represents the merger at the University of California San Francisco of scientists working in pharmaceutical sciences, drug development and contemporary genetics. The graduate program reflects the exciting scientific developments in the area of genomics, quantitative and systems biology, and computation that have far-reaching implications to the pharmaceutical and pharmacological sciences. The goal of the PSPG Graduate Program is to educate students to address the major questions in the pharmaceutical sciences, teach students the basic sciences needed to address these questions, and create an environment where the students can develop into independent and creative scientific problem solvers. The program brings together 50 faculty members spanning 18 departments with well-funded research programs. This multidisciplinary graduate program has a dual focus: 1) pharmaceutical sciences and drug development, including molecular and systems pharmacology, drug delivery and therapeutic bioengineering, drug metabolism and transport, and pharmacokinetics/pharmacodynamics;and 2) pharmacogenomics, which includes clinical, functional and computational genomics related to drug disposition and response. The training program includes a series of core courses providing an in- depth understanding of the principles of pharmaceutical sciences and pharmacogenomics, complemented by core and general electives covering advanced drug delivery and pharmacokinetic principles, principles of genetics and cell biology, bioinformatics, tissue and organ biology, and advanced statistics. Students also participate in laboratory rotations that expose them to the diversity of potential projects available for their dissertation research and a university-wide course on responsible conduct of research. The program immerses young scientists in the culture of science through a seminar program in pharmaceutical sciences and pharmacogenomics which brings in leading academic and industrial scientists, student research presentations, and an annual retreat. The program goal is to recruit 12 outstanding students per year for a total training program of 60 students. Underrepresented students are actively recruited through a number of faculty activities and represent approximately 10% of our students. Our program is one of the very few in the world with faculty expertise that spans the fields of pharmaceutics, genetics and computation;hence the training program is ideally situated to educate future scientific leaders in the emerging research areas at the intersection of these disciplines. The integrative approach has resulted in Ph.D. graduates who have the insight and quantitative scientific tools required for success in the rapidly advancing fields of drug development and pharmacogenomics;consequently graduates from the program are in high demand in academia, government and industry.

Public Health Relevance

There is an increasing need for the development of new and effective drug therapies for the treatment of disease that can be tailored for individual patients. Students in the Pharmaceutical Sciences and Pharmacogenomics Graduate Program are trained to be future scientific leaders in this area. Their training will prepare them to develop effective treatment strategies for existing and newly developed drugs that consider the principles of pharmacology and our advancing knowledge of personal genetics.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
National Institute of General Medical Sciences Initial Review Group (BRT)
Program Officer
Okita, Richard T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Schools of Pharmacy
San Francisco
United States
Zip Code
Asmussen, Jennifer; Lasater, Elisabeth A; Tajon, Cheryl et al. (2014) MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction. Cancer Discov 4:200-15
Chen, Ligong; Shu, Yan; Liang, Xiaomin et al. (2014) OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci U S A 111:9983-8
Smith, Robin P; Eckalbar, Walter L; Morrissey, Kari M et al. (2014) Genome-wide discovery of drug-dependent human liver regulatory elements. PLoS Genet 10:e1004648
Drake, Katherine A; Torgerson, Dara G; Gignoux, Christopher R et al. (2014) A genome-wide association study of bronchodilator response in Latinos implicates rare variants. J Allergy Clin Immunol 133:370-8
Fox, Cade B; Chirra, Hariharasudhan D; Desai, Tejal A (2014) Planar bioadhesive microdevices: a new technology for oral drug delivery. Curr Pharm Biotechnol 15:673-83
Yago, Marc R; Frymoyer, Adam; Benet, Leslie Z et al. (2014) The use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria. AAPS J 16:1358-65
Lowe, Margaret M; Mold, Jeff E; Kanwar, Bittoo et al. (2014) Identification of cinnabarinic acid as a novel endogenous aryl hydrocarbon receptor ligand that drives IL-22 production. PLoS One 9:e87877
Poole, Alex; Urbanek, Cydney; Eng, Celeste et al. (2014) Dissecting childhood asthma with nasal transcriptomics distinguishes subphenotypes of disease. J Allergy Clin Immunol 133:670-8.e12
Birnbaum, Ramon Y; Patwardhan, Rupali P; Kim, Mee J et al. (2014) Systematic dissection of coding exons at single nucleotide resolution supports an additional role in cell-specific transcriptional regulation. PLoS Genet 10:e1004592
Wiita, Arun P; Seaman, Julia E; Wells, James A (2014) Global analysis of cellular proteolysis by selective enzymatic labeling of protein N-termini. Methods Enzymol 544:327-58

Showing the most recent 10 out of 55 publications